Puma Biotechnology Inc. (PBYI) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Puma Biotechnology Inc.

    NASDAQ: PBYI · Real-Time Price · USD
    5.03
    -0.08 (-1.57%)
    At close: Sep 05, 2025, 3:59 PM
    5.13
    1.99%
    After-hours: Sep 05, 2025, 07:23 PM EDT

    Puma Biotechnology Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 230.47M 235.64M 228M 253.2M
    Cost of Revenue
    		 64.4M 62.68M 55.1M 63.7M
    Gross Profit
    		 166.06M 172.96M 172.9M 189.5M
    Operating Income
    		 30.97M 32.64M 23.7M 1.29M
    Interest Income
    		 4.72M 2.6M 813K 100K
    Pretax Income
    		 24.1M 22.67M 457K -28.8M
    Net Income
    		 30.28M 21.59M 2K -29.1M
    Selling & General & Admin
    		 80.16M 89.31M 90M 116.3M
    Research & Development
    		 54.94M 50.38M 52.2M 71.9M
    Other Expenses
    		 n/a 625K 7.02M n/a
    Operating Expenses
    		 135.1M 140.31M 149.22M 188.2M
    Interest Expense
    		 12.45M 13.33M 11.59M 12.8M
    Selling & Marketing Expenses
    		 -519K 881K 22K 6K
    Cost & Expenses
    		 199.5M 203M 204.31M 251.9M
    Income Tax Expense
    		 -6.18M 1.08M 500K 324K
    Shares Outstanding (Basic)
    		 48.65M 47.13M 44.67M 40.64M
    Shares Outstanding (Diluted)
    		 49.1M 47.55M 44.93M 40.64M
    EPS (Basic)
    		 0.62 0.46 0.02 -0.72
    EPS (Diluted)
    		 0.62 0.45 0.02 -0.72
    EBITDA
    		 48.08M 47.52M 20.97M -5.4M
    EBIT
    		 36.55M 36M 12.05M -15.99M
    Depreciation & Amortization
    		 11.52M 11.52M 8.92M 10.6M

    Add to Watchlist